Triptolide sensitizes cancer cells to nucleoside DNA methyltransferase inhibitors through inhibition of DCTPP1-mediated cell-intrinsic resistance

Author:

Liu Jianyong,He Qing-Li,Zhou Jianya,Chikarmane Roshan,Hauk Glenn,Rachakonda Archana,Vaghasia Ajay M.,Castagna Nicole,Steinberg Ruchama C.,Pham Minh-Tam,Anders Nicole M.,Wanjiku Teresia M.,Nuhn Philipp,Shim Joong Sup,Giovinazzo Hugh,Esopi David M.,Kim Kunhwa,Coulter Jonathan,Wang Rulin,Zhou Jianying,Rudek Michelle A.,Berger James M.,Liu Jun O.,Nelson William G.,Yegnasubramanian Srinivasan

Abstract

SUMMARYWhile nucleoside DNA methyltransferase inhibitors (DNMTi) such as decitabine and azacitidine are effective in treating myelodysplatic syndrome (MDS)/leukemia, they have had limited utility for the majority of other cancers. Through a chemical library screen, we identified that triptolide, a diterpenoid epoxide fromTripterygium wilfordii, or analogs significantly augmented the epigenetic and anti-cancer effects of decitabinein vitroandin vivo. These effects were attributable to inhibition of DCTPP1-mediated cleavage of 5-aza-deoxycytidine triphosphate, the convergent activated metabolite of nucleoside DNMTi, leading to enhanced drug incorporation into genomic DNA, increased DNMT degradation, enhanced global DNA demethylation and associated transcriptional reprogramming. We show that high DCTPP1 expression was associated with cell-intrinsic resistance to nucleoside DNMTi, and that triptolide and its analogs could overcome this resistance.SIGNIFICANCEWe screened a library of existing drugs to identify those capable of enhancing the anti-cancer effects of the nucleoside DNMTi decitabine. The combination of triptolide and decitabine synergistically inhibited cancer cell growth and survivalin vitro, and was highly effective in inhibiting xenograft growthin vivo. Biochemical, genetic and structural biology studies with triptolide and its analogs revealed that this synergy was due to their inhibition of DCTPP1-mediated pyrophosphate cleavage from 5-aza-deoxycytidine triphosphate, the active metabolite of DNMTi. The genomic incorporation and efficacy of decitabine in cancer cell lines were significantly correlated with DCTPP1 expression more so than those of other nucleoside metabolizing genes. Triptolide and its analogs comprise rational adjuncts to nucleoside DNMTi ripe for further pre-clinical/clinical translation.HIGHLIGHTSTriptolide synergistically sensitizes cancer cells to DNMTiin vitro.Triptolide and decitabine combination shows favorable efficacy and safetyin vivo.Synergy of triptolide and decitabine is mediated through inhibition of DCTPP1.High DCTPP1 expression confers cell intrinsic resistance to DNMTi.

Publisher

Cold Spring Harbor Laboratory

Reference83 articles.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3